May 8 (Reuters) - Viatris Inc VTRS.O:
VIATRIS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM TWO PIVOTAL PHASE 3 STUDIES OF NOVEL FAST-ACTING MELOXICAM (MR-107A-02) FOR THE TREATMENT OF MODERATE-TO-SEVERE ACUTE PAIN
VIATRIS INC: ALL PRIMARY AND SECONDARY ENDPOINTS WERE MET IN BOTH PHASE 3 STUDIES
VIATRIS INC: TARGETING NEW DRUG APPLICATION SUBMISSION TO U.S. FDA BY END OF 2025
Source text: ID:nPnRMpfwa
Further company coverage: VTRS.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.